Facebook Pixel Code
Banner image
Drugs and Breastfeeding

IBD and Breastfeeding

Breastfeeding, inflammation and infant development

Inflammatory bowel disease (IBD) is one of the chronic conditions that is associated with inflammation of the lining of digestive system and often affects women during their childbearing years. Like many other inflammatory conditions, IBD is associated with an abnormal function of the immune system in our body, along with high levels of certain proteins that cause inflammation (like Tumour Necrosis Factor alpha or TNFα). New treatments called “biologics” that are made out of living sources (in contrast to most drugs which are chemically manufactured) can target and stop these proteins from causing inflammation. Biologics have been effectively used for treatment of many inflammatory conditions including IBD over the last decade.

In order to learn more about the safety of biologics, it is important to measure their concentration in breast milk while considering their interaction with their target, TNFα.
In fact, TNFα and similar proteins are also present variably in breast milk of healthy mothers and may play a role in development of an infant’s brain and immune system. For this reason, it is important to learn more about TNFα concentration, as well as its relation with biologics in breast milk of women with IBD.

Why do we do this study?

We are undertaking this study, because we want to investigate:

  • Concentration of inflammatory proteins like TNFα in breast milk
  • Interaction between TNFα and biologics in breast milk of mothers with IBD and its effect on measuring biologics in breast milk, correctly
  • Potential role of TNFα and biologics in the development of infant learning and memory function

With our research findings, we hope to provide information that is necessary for evaluating safety of biologics for infants, when they are exposed via breast milk.

Who do we study?

We enrol two groups of participants in our study: